So i've been watching this stock for a while and I think I'm missing something. It's a mid-sized Biotech company called Chimerix (NASDAQ:CMRX) which traded for $53.74 in mid-late 2015. The stock has since dropped to $5.29 (even as low as $3.49 for a little bit) due to some troublesome results from a trial. It turns out that the discovery of the problem with their new drug was in fact a misdiagnosis. Not only that, but they changed it from a pill to an IV and the new drug can actually treat more than what it was originally designed to treat (some of these ailments are without a cure at the moment). They have also made several promotions for higher ups, one of which is Chief of production (which leads me to believe they have a new drug going into production in the future). So what am I missing? You would think that a biotech company that used to trade in the $50's but then dropped due to a misdiagnosis would rebound better than this...
It's like the only thing the analysts can see is their earnings and revenue - shouldn't they look at the growth potential? After all, what made it trade for ten times as much a year ago? So i'm curious to hear from the Reddit community. Is this company just overlooked? Was it overvalued in the past and investors know better this time around? Why is this company not in the sights of more analysts?
Submitted February 03, 2017 at 11:58AM by SilkyRibbon http://ift.tt/2ka8VjC
